Cargando…
Novel antiplatelet agents in the prevention of cardiovascular complications – focus on ticagrelor
Atherothrombosis, thrombus formation as a result of atherosclerotic plaque rupture, is a major modern health problem, often underlying coronary artery disease, stroke, and peripheral arterial disease. After the treatment of an acute thrombotic episode, long-term therapy is warranted as a secondary p...
Autores principales: | Marczewski, Margaret M, Postula, Marek, Kosior, Dariusz |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2882894/ https://www.ncbi.nlm.nih.gov/pubmed/20539844 |
Ejemplares similares
-
Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor
por: Birkeland, Kade, et al.
Publicado: (2010) -
Emerging treatments in type 2 diabetes: focus on canagliflozin
por: Rosiak, Marek, et al.
Publicado: (2014) -
Ticagrelor: An emerging oral antiplatelet agent
por: Juneja, Shivani, et al.
Publicado: (2013) -
Ticagrelor: The first approved reversible oral antiplatelet agent
por: Goel, Divya
Publicado: (2013) -
Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor
por: Davis, Estella M, et al.
Publicado: (2013)